BMY — Bristol-Myers Squibb Company

Q2 2026 adjusted EPS of $2.04 beat the ~$1.60 consensus and revenue grew 5.7% YoY to $12.97B. Management raised FY2026 revenue guidance to $49–50B and adjusted EPS to $6.75–$7.00, while the Growth Portfolio (+15% YoY to $7.6B) and Eliquis (+21% to $4.5B) are offsetting Revlimid erosion. That combination has pushed the stock near its 52-week high and keeps Wall Street broadly constructive.

The inflection is real but only one quarter old: YoY revenue growth was +0.6% in Q2 2025, roughly +1–3% in Q3/Q4 2025, +2.6% in Q1 2026, then accelerated to +5.7% in Q2 2026. Operating margin has improved from the low-20s in 2024 and the charge-hit Q4 2025 to roughly 29–31.5% in H1 2026. GAAP net income is noisy due to one-off items — Q1 2024 was a -$11.9B loss and Q4 2025 was depressed to $1.09B — so adjusted/forward metrics matter more than trailing GAAP. Free cash flow remains strong but lumpy: TTM FCF is ~$11.4B versus ~$12.8B in FY2025.

At $66.95, BMY trades at 14.7x trailing GAAP EPS versus a 5-year average of 18.2x, but trailing EPS understates earnings power because of charges. Using the raised FY2026 adjusted EPS midpoint of $6.875, forward P/E is roughly 9.7x. Price/sales of 2.78x is only slightly above the 5-year average of 2.66x, and the 4.32% dividend yield plus low PEG make the stock look fair-to-cheap on forward earnings — with the discount reflecting patent-cliff and balance-sheet risk.

The stock has rallied sharply in 2026 and as of 2026-08-27 trades just below the consensus target of $69, with the high target at $75. The market is beginning to price in the growth portfolio offsetting Revlimid, but it is not yet paying up for sustained EPS acceleration. If Q3 2026 confirms the raised $49–50B revenue and $6.75–$7.00 EPS guidance, the stock can grind toward the $72–75 area; if momentum stalls, the low forward multiple offers only modest downside protection because expectations have already reset upward.

As of 2026-08-27, RSI(14) was 60.21 — bullish but not overbought. Price was +2.19% vs the 20-day SMA, +8.97% vs the 50-day, and +16.32% vs the 200-day, so the trend is clearly up after a large 2026 rally. Entry timing is less favorable here: chasing after a 16% premium to the 200-day near the 52-week high carries pullback risk; a dip toward the 20/50-day moving averages would offer a better risk/reward.

• Stabilizing interest rates are driving income rotation into high-dividend large-cap pharma; BMY yields ~4.3%.
• Roughly 70% of sales are U.S.-based, exposing BMY to domestic drug-pricing and IRA negotiation headlines.
• Patent-cliff dynamics — Revlimid still -49% YoY in Q2 2026 and Eliquis long-term LOE risk — keep a structural discount on the multiple.
• Large-cap pharma M&A and pipeline licensing remain sector themes, though BMY's debt load limits but does not eliminate dealmaking.
• Healthcare sector momentum and broader risk appetite are supporting the stock after its strong YTD run.

• Q3 2026 earnings in late October 2026 — the key test of whether the Q2 beat and raised guidance are durable.
• Continued Growth Portfolio momentum: Reblozyl +29%, Breyanzi +41%, Camzyos +59%, Opdivo Qvantig, and KarXT ramp.
• Pipeline readouts and trial initiations, including EDG-15400 Phase II in HFpEF expected in 2H 2026.
• Debt reduction and cash generation: TTM FCF ~$11.4B supports deleveraging and the dividend.

• Revlimid's -49% erosion continues, and eventual Eliquis LOE or U.S. pricing pressure could re-accelerate revenue decline.
• High leverage: debt-to-equity ~1.93 and long-term debt of $42.1B; rising rates or a credit downgrade would pressure the story.
• Execution/integration risk on new launches and pipeline; a clinical or regulatory setback would dent the growth thesis.
• The stock has already repriced from $42.52 to ~$67, leaving limited upside to the $69 consensus and $75 high target.

BMY is a financially healthy pharma with a visible growth inflection — Q2 beat, raised guidance, Growth Portfolio +15%, forward P/E ~9.7x, and a 4.3% dividend yield — but the patent cliff, ~$42B debt, and the fact the stock has already rallied to near analyst targets make the current risk/reward balanced rather than compelling. It is a reasonable core income/defensive holding, not an obvious high-conviction buy at $66.95.

Fair value = FY2026E adjusted EPS midpoint of $6.875 × a justified P/E of 10.9x. I used 10.9x — well below BMY's 5-year average of 18.2x — to reflect patent-cliff exposure, ~1.9x debt/equity, and U.S. pricing risk, while still crediting the 4.3% dividend yield, ~30% operating margin, and growth portfolio inflection. That yields roughly $75, above the $69 consensus target but below any historical-multiple-based bull case.